Sebastian M Christ, Filippo Alongi, Umberto Ricardi, Marta Scorsetti, Lorenzo Livi, Panagiotis Balermpas, Yolande Lievens, Pètra Braam, Barbara Alicja Jereczek-Fossa, Karin Stellamans, Ivica Ratosa, Joachim Widder, Heike Peulen, Piet Dirix, Samuel Bral, Sara Ramella, Hossein Hemmatazad, Kaouthar Khanfir, Xavier Geets, Paul Jeene, Thomas Zilli, Beatrice Fournier, Giovanni Battista Ivaldi, Enrico Clementel, Catherine Fortpied, Felix Boakye Oppong, Piet Ost, Matthias Guckenberger
BACKGROUND AND INTRODUCTION: Optimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation. MATERIALS AND METHODS: Analysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using α/β of 10 Gy for all primaries, and cancer-specific α/β of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2...
March 18, 2024: Radiotherapy and Oncology